Aptevo Therapeutics Inc. (APVO) Fair Value 2026

APVO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (46/100)

Quick Summary — As of 2026-08-28, Aptevo Therapeutics Inc. (APVO) trades at $2.37. QOC: 4.3/10. Value Trap Risk: 46/100 (WARN). 1/13 models active.

Key Facts

Ticker
APVO
Price
$2.37
Quality Score
4.3/10
Value Trap Risk
46/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +177.5% upside with 27% confidence
Risk: Value Trap score of 46 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give APVO?

1 Intrinsic Value Models vs. Current Price ($2.37)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $6.56 +177.5%

All Models Active

All 1 models are displayed above.

What Is Aptevo Therapeutics Inc. (APVO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Aptevo Therapeutics Inc.'s intrinsic value is estimated at a median fair value of $6.56. At a current market price of $2.37, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +177.5%.

What Do the Models Say About APVO?

1 of 13 models are currently active for APVO. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does APVO Rank in Biotechnology?

Among 625 Biotechnology stocks, APVO ranks #485 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Aptevo Therapeutics Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is APVO a Value Trap?

CirclFi's Value Trap algorithm assigns APVO a score of 46/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Aptevo Therapeutics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Aptevo Therapeutics Inc. earns a quality score of 4.3/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every APVO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across APVO's 1 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Aptevo Therapeutics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ACHVAchieve Life Sciences, Inc.QOC 4.3CNSPCNS Pharmaceuticals, Inc.QOC 4.3JBIOJade Biosciences, Inc.QOC 4.3KLRSKalaris Therapeutics, Inc.QOC 4.3ONCOOnconetix, Inc.QOC 4.3ANVSAnnovis Bio, Inc.QOC 4.3BMRNBioMarin Pharmaceutical Inc.QOC 8.6DNAGinkgo Bioworks Holdings, Inc.QOC 5.8DRUGBright Minds Biosciences Inc.QOC 5.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ACHV · CNSP · JBIO · KLRS · ONCO · ANVS · BMRN · DNA · DRUG · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to APVO?

6 companies across all industries closest to APVO’s Quality of Company score of 4.3/10.

MWAIMedwellAI, Inc.QOC 4.3NAKANakamoto Inc.QOC 4.3STQNStrategic Acquisitions, Inc.QOC 4.3MTWOM2i Global, Inc.QOC 4.3XHGXChange TEC.INCQOC 4.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MWAI · NAKA · STQN · MTWO · XHG · NVDA

Where Does APVO Sit in CirclFi's Biotechnology Rankings?

APVO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Aptevo Therapeutics Inc.’s Valuation?

What is Aptevo Therapeutics Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Aptevo Therapeutics Inc. (APVO). The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is APVO overvalued or undervalued right now?

At $2.37, 1 of 1 active models suggest APVO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Aptevo Therapeutics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.3 mean for APVO?

Aptevo Therapeutics Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on APVO?

CirclFi analyzes APVO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is APVO a value trap in 2026?

Aptevo Therapeutics Inc.'s Value Trap score is 46/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Aptevo Therapeutics Inc. (APVO) a Quality of Company score of 4.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/APVO/ · Methodology
Primary sources for this APVO valuation
  • Financial statements: Aptevo Therapeutics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001671584) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for APVO as of ; valuations recomputed .